Endocrine Deep Dives podcast

Crinecerfont for Steroid Reduction in CAH

0:00
21:07
Rewind 15 seconds
Fast Forward 15 seconds

This episode evaluates crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, for classic congenital adrenal hyperplasia. By blocking pituitary ACTH secretion independently of glucocorticoid feedback, crinecerfont reduces adrenal androgen excess, including androstenedione. This mechanism permits significant supraphysiologic glucocorticoid dose reduction toward physiologic replacement levels, mitigating long-term iatrogenic metabolic and skeletal complications while preserving adrenal control.


More episodes from "Endocrine Deep Dives"